Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and Invasiveness, Neoplasm

lestaurtinib has been researched along with Invasiveness, Neoplasm in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adriaenssens, E; Aubert, L; Bertucci, F; Chassat, T; Corbet, C; Daubon, T; Génot, E; Guilbert, M; Le Bourhis, X; Magné, N; Toillon, RA1
Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C1
Dionne, CA; Klein-Szanto, AJ; Miknyoczki, SJ; Ruggeri, BA1
Chang, H; Dionne, CA; Klein-Szanto, A; Miknyoczki, SJ; Ruggeri, BA1

Other Studies

4 other study(ies) available for lestaurtinib and Invasiveness, Neoplasm

ArticleYear
NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib.
    Oncotarget, 2015, Volume: 6, Issue:12

    Topics: Animals; Biotinylation; Carbazoles; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Female; Furans; Gene Silencing; Humans; Hyaluronan Receptors; Immunoprecipitation; Mass Spectrometry; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Nerve Growth Factor; Protein Binding; Proteomics; Receptor, trkA; RNA, Small Interfering; Signal Transduction

2015
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    International journal of oncology, 2007, Volume: 30, Issue:1

    Topics: Brain-Derived Neurotrophic Factor; Carbazoles; Cell Line, Tumor; Enzyme Inhibitors; Furans; Humans; Indoles; Male; Neoplasm Invasiveness; Nerve Growth Factors; Prostatic Neoplasms; Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Androgen

2007
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
    Annals of the New York Academy of Sciences, 1999, Jun-30, Volume: 880

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbazoles; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor Protein-Tyrosine Kinases; Trachea

1999
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured

1999